← Back to Search

Antipsychotic

Risperidone for Huntington's Disease

Phase 2
Waitlist Available
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12
Awards & highlights

Study Summary

This trial will study whether risperidone is a safe and effective treatment for involuntary movements (chorea) in Huntington's disease.

Eligible Conditions
  • Huntington's Disease
  • Chorea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) score
Secondary outcome measures
Chorea Index as measured by BioStamp nPoint device
Columbia Suicide Severity Rating Scale( C-SSRS)
Q-Motor (quantitative motor) assessments of chorea
+10 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: RisperidoneExperimental Treatment2 Interventions
Participants will initiate risperidone 0.5 mg nightly the day after the baseline visit. Dose assessment will occur at pre-specified intervals during the titration phase (week 2, 3, 4, 6, 7). The investigator will increase the dose by 0.5 mg at the week 2, week 3, week 4, and week 6 visits until either optimal chorea benefit has been obtained, an intolerable adverse event occurs, or the maximum allowable dose (3.0 mg) is reached.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Risperidone
2011
Completed Phase 4
~3550
BioStamp nPoint device
2020
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
836 Previous Clinical Trials
518,163 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Which medical conditions usually benefit from Risperidone treatments?

"Risperidone is therapeutically used to treat acute coryza, autistic disorder and bipolar illness."

Answered by AI

Is there a specific demographic of individuals that would be considered apt for this research project?

"We are actively recruiting 12 individuals, aged between 18 and 65 years old, who have been diagnosed with Huntington disease. To be eligible for this trial, patients must also meet the age criteria of being over 18 and under 65."

Answered by AI

Is this research study open to individuals over the age of 35?

"This medical trial is seeking individuals of legal age and below the retirement threshold."

Answered by AI

Has the recruitment process for this research project been initiated yet?

"This particular medical trial, as evidenced by its listing on clinicaltrials.gov is still actively enrolling patients. It was initially posted in August 13th 2020 and the last update took place in November 2nd 2021."

Answered by AI

Has Risperidone been given the nod from the FDA?

"The safety of risperidone was assessed at a score of 2 as this is currently being tested in Phase 2 trials, with some data supporting its saftey but no evidence yet on efficacy."

Answered by AI

Could you provide a synopsis of other Risperidone experiments that have been conducted?

"Currently, there is one Phase 3 Risperidone trial and 17 other ongoing studies. Toronto, Ontario hosts most of the research; however, a total of 139 locations are currently conducting experiments with this medication."

Answered by AI

What is the cap on total participants for this medical experiment?

"Affirmative. Clinicaltrials.gov's data shows that this clinical study, first uploaded on August 13th 2020, is presently seeking participants. The research requires 12 individuals to be recruited from one medical centre."

Answered by AI

Who else is applying?

How old are they?
< 18
18 - 65
What site did they apply to?
URMC Neurology; 919 Westfall Rd, Building C, Suite 100
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Risperidone for the Treatment of Huntington's Disease Involuntary Movements
Ruth Schneider, MD 2020. "Risperidone for the Treatment of Huntington's Disease Involuntary Movements". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04201834.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top